HLA-A*0201 & B2M & MAGE-A4 (KVLEHVVRV)
HLA-A*0201 & B2M & MAGE-A4 (KVLEHVVRV) 제품 목록
- 속성
Protein (2)
- 제품 라이브러리
온라인 (2)
- 종
Human (2)
- 태그
His Tag & Avi Tag (1)His Tag (1)
- 마커
Biotin-labeled (1)PE Labeled (1)
| 제품 번호 | 종 | 발현 시스템 | 제품 설명 | 단백질 구조 | 순도 | 특성 |
|---|---|---|---|---|---|---|
 Human | HEK293 | Biotinylated Human HLA-A*02:01&B2M&MAGE-A4 (KVLEHVVRV) Complex Protein (Monomer, MALS verified) |  |  | ||
| Human | HEK293 | PE-Labeled Human HLA-A*02:01&B2M&MAGE-A4 (KVLEHVVRV) Tetramer Protein |
총 수량2
- 1
HLA-A*0201 & B2M & MAGE-A4 (KVLEHVVRV)분자 배경
The MAGE A4 antigen is a cancer-testis antigen and is expressed intracellularly in various solid tumor tissues, MAGE peptide (KVLEHVVRV) is a cytotoxic T lymphocyte (CTL) epitope presented by HLA-A2 The Human HLA-A*0201. MAGE-A4 (KVLEHVVRV) complex protein is a complex of HLA-A*0201 of the MHC Class I, B2M, and KVLEHVVRV peptide of the MAGE-A4.
임상 약물 정보
| 영어 이름 | 연구 코드 | 연구 개발 단계 | 회사 | 적응증 | 임상 시험 |
|---|---|---|---|---|---|
| Ecopipam | PSYRX-101; Sch-39166 | Phase 3 Clinical | Merck Sharp & Dohme Corp | Language Disorders; Speech Disorders; Self-Injurious Behavior; Lesch-Nyhan Syndrome; Childhood-Onset Fluency Disorder; Tourette Syndrome; Gambling; Stuttering | 상세 |
| Tavapadon | CVL-751; PF-6649751; PF-06649751 | Phase 3 Clinical | Pfizer Inc, Cerevel Therapeutics Llc | Kidney Diseases; Parkinson Disease; Hepatic Insufficiency | 상세 |
| Thioridazine | TP-21 | Phase 3 Clinical | Novartis Pharma Ag | Schizophrenia; Anxiety Disorders; Carcinoma, Hepatocellular | 상세 |
| Olanzapine long acting injectable (Teva Pharmaceutical Industries) | TV-44749; TEV-‘749; mdc-TJK | Phase 3 Clinical | Medincell SA | Schizophrenia | 상세 |
| PF-06412562 | PF-6412562; PF-06412562 | Phase 2 Clinical | Pfizer Inc | Schizophrenia; Schizophrenia Spectrum and Other Psychotic Disorders; Parkinson Disease | 상세 |
| Mevidalen | LY-3154207 | Phase 2 Clinical | Eli Lilly And Company | Parkinson Disease; Lewy Body Disease | 상세 |
| TGOF02N | TGOF-02N; TGOF02N; FKF02SC | Phase 2 Clinical | Fabre-Kramer | Schizophrenia | 상세 |
| ASP-4345 | ASP-4345 | Phase 2 Clinical | Astellas Pharma Inc | Schizophrenia | 상세 |
| Docarpamine (Martin Pharmaceuticals) | Phase 2 Clinical | Martin Pharmaceuticals Inc | Gastrointestinal Diseases; Liver Cirrhosis; Mouth Diseases | 상세 | |
| CVL-871 | CVL-871 | Phase 2 Clinical | Pfizer Inc | Dementia | 상세 |
| [11C]NNC-112 | [11C]NNC-112 | Phase 2 Clinical | Glaxosmithkline Plc | Diagnostic agents | 상세 |
| Lu-AF-28996 | Phase 1 Clinical | H. Lundbeck A/S | Parkinson Disease | 상세 | |
| Olanzapine intranasal (Neurelis) | NRL-4; NRL-1004 | Phase 1 Clinical | Neurelis Inc | Bipolar Disorder | 상세 |
| Oxytocin/Methylergometrine Maleate | Phase 1 Clinical | Nanjing Gritpharma Co Ltd | Hemorrhage; Obstetric Labor Complications | 상세 | |
| ITI-333 | ITI-333 | Phase 1 Clinical | Intra-Cellular Therapies Inc | Mood Disorders; Pain; Opioid-Related Disorders | 상세 |
| PF-06730110 | PF-06730110; [18F]MNI-968 | Phase 1 Clinical | Invicro Llc | Nerve Degeneration | 상세 |
시판 약물 정보
| 영어 이름 | 연구 코드 | 연구 개발 단계 | 회사 | 가장 빠른 브랜드 이름 | 가장 빠른 승인 국가 | 가장 빠른 적응증 | 가장 빠른 승인 회사 | 가장 빠른 승인 날짜 | 적응증 | 임상 시험 |
|---|---|---|---|---|---|---|---|---|---|---|
| Docarpamine | TA-870; TA-8704 | Approved | Tanadopa | Heart Failure | null | 1994-01-01 | Heart Failure | 상세 | ||
| Olanzapine/Fluoxetine hydrochloride | OFC | Approved | Eli Lilly And Company | Symbyax | United States | Bipolar Disorder | Eli Lilly And Company | 2003-12-24 | Depressive Disorder, Major; Bipolar Disorder; Depressive Disorder; Depressive Disorder, Treatment-Resistant | 상세 |
| Zuclopenthixol Hydrochloride | LU-0108 | Approved | Clopixol | Bipolar Disorder; Schizophrenia | null | 1962-01-01 | Schizophrenia; Bipolar Disorder | 상세 | ||
| Methylergometrine Maleate | Approved | Metenarin, Methergine, Ryegonivin, Basofortina, Methylergobrevin | Postpartum Hemorrhage; Uterine Cervical Incompetence; Uterine Hemorrhage; Uterine Inertia | 상세 | ||||||
| Samidorphan/Olanzapine | ALKS-3831 | Approved | Alkermes Plc | Lybalvi | United States | Bipolar Disorder; Schizophrenia | Alkermes Inc | 2021-05-28 | Schizophrenia; Bipolar Disorder; Psychotic Disorders; Bipolar and Related Disorders; Alcoholism | 상세 |
| Olanzapine | LY-170053; INP-105; TEV-‘749; LY-170052; ALKS-7921 | Approved | Eli Lilly And Company | Zyprexa Relprevv, Olansek, Zyprexa Zydis, Olanzapine ODF, 再普乐, Midax, Lanzac, Zyprexa, Zypadhera, Zalasta, Zyprexa Velotab | EU | Schizophrenia; Bipolar Disorder | null | 1996-09-27 | Opioid-Related Disorders; Chemotherapy-induced nausea and vomiting; Fasting; Anorexia Nervosa; Borderline Personality Disorder; Depressive Disorder, Treatment-Resistant; Gambling; Nausea; Vomiting; Postoperative Nausea and Vomiting; Emergence Delirium; Feeding and Eating Disorders; Malaria, Falciparum; Autistic Disorder; Hematologic Neoplasms; Neoplasms; Insulin Resistance; Anorexia; Bipolar Disorder; Psychotic Disorders; Bipolar and Related Disorders; Depression; Stomach Neoplasms; Depressive Disorder, Major; Schizophrenia; Substance-Related Disorders; Weight Loss; Solid tumours | 상세 |
| Phenylpropanolamine Hydrochloride | Approved | Nasadec, Nasathera, Pararhinol | Nasal Obstruction | 상세 | ||||||
| Fenoldopam Mesylate | SKF-82526; SKF-82526J; (±)-SKF-82526 | Approved | Abbott Laboratories | Corlopam | United States | Hypertension | Hospira Inc | 1997-09-23 | Hypertension | 상세 |
| Olanzapine/Hydroxyzine pamoate | Approved | Nausea | 상세 | |||||||
| Stepholidine | Approved | Mainland China | Headache; Attention Deficit Disorder with Hyperactivity; Tourette Syndrome; Migraine Disorders | null | 1995-01-01 | Headache; Migraine Disorders; Attention Deficit Disorder with Hyperactivity; Tourette Syndrome | 상세 |
- 제품 목록
- 시판 약물 정보
- 임상 약물 정보